BOSTON, Apr 17, 2009 (BUSINESS WIRE) -- Orthofix International N.V., (NASDAQ:OFIX) (the Company) today announced
preliminary results for the first quarter of 2009, indicating that the
Company expects to report total revenue of approximately $129.0 million
and earnings in the range of $0.14 to $0.16 per diluted share. The
Company's spine implant and biologic businesses generated total revenue
of approximately $28.8 million during the quarter.
"We were especially pleased with our preliminary first quarter results
which included a negative foreign currency impact of approximately $5.1
million on total revenue and better than expected results at our spine
implant and biologic businesses," said Orthofix President and CEO Alan
Milinazzo.
Orthofix also announced that it will host a conference call and webcast
on Wednesday, May 6th at 4:30 PM Eastern Time to discuss the Company's
final results for the first quarter ended March 31, 2009, which will be
released at approximately 4:00 PM that same day.
Interested parties may access the conference call by dialing (866)
626-7622 in the U.S. and Canada and (706) 758-3283 outside the U.S., and
entering the conference ID 95863375. A replay of the call will be
available for one week by dialing (800) 642-1687 in the U.S. and (706)
645-9291 outside the U.S., and entering the conference ID 95863375. A
webcast of the conference call may be accessed by going to the company's
website at www.orthofix.com,
by clicking on the Investors link and then the Events and Presentations
page.
About Orthofix International, N.V.
Orthofix International N.V., a global medical device company, offers a
broad line of minimally invasive surgical, as well as non-surgical,
products for the spine, orthopedic, and sports medicine market sectors
that address the lifelong bone-and-joint health needs of patients of all
ages, helping them achieve a more active and mobile lifestyle.
Orthofix's products are widely distributed around the world to
orthopedic surgeons, hospitals and patients via Orthofix's sales
representatives and its subsidiaries, including Breg, Inc. and
Blackstone Medical, Inc. In addition, Orthofix is collaborating in R&D
partnerships with leading institutions such as the Musculoskeletal
Transplant Foundation, the Orthopedic Research and Education Foundation,
the Musculoskeletal Transplant Foundation, and the National Osteoporosis
Institute. For more information about Orthofix, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of Orthofix and its subsidiaries and are based on
management's current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ
materially from those contemplated by the forward-looking statements.
Factors that could cause or contribute to such differences may include,
but are not limited to, risks relating to the expected sales of its
products, including recently launched products, unanticipated
expenditures, changing relationships with customers, suppliers and
strategic partners, risks relating to the protection of intellectual
property, changes to the reimbursement policies of third parties,
changes to and interpretation of governmental regulation of medical
devices, the impact of competitive products, changes to the competitive
environment, the acceptance of new products in the market, conditions of
the orthopedic industry and the economy, corporate development and
market development activities, including acquisitions or divestitures,
unexpected costs or operating unit performance related to recent
acquisitions and other factors described in our annual report on Form
10-K and other periodic reports filed by the Company with the Securities
and Exchange Commission.
SOURCE: Orthofix International N.V.
Orthofix International N.V.
Dan Yarbrough, 617-912-2903
Vice President of Investor Relations
danyarbrough@orthofix.com
Copyright Business Wire 2009